Patents Assigned to Los Angeles Biomedical Research Institute
-
Patent number: 9119590Abstract: A technique for measuring thoracic vertebral bone density (BMD) and coronary calcium score (CCS). Representatively, BMD was measured and averaged at three consecutive thoracic spines (3T) starting from the left main coronary artery caudally and averaging the results of the measurements at the first, second and third spine regions to obtain a thoracic trabecular bone mineral density measurement. The “reference”, as the 3T BMD value of 30 year old and the piBMD (predicted individual BMD (piBMD) were developed. Based on the “reference”, and piBMD, T and Z score of 3T formula were derived in both genders. The new calibration phantom of TQCT and LQCT was designed. The ratios of CTHU/mg/cc were obtained with varying scanners, which were used to translate the CTHU to density units (mg/cc) in BMD and CCS mass measurement. A processor capable of quantitating both BMD and CCS burden was designed. In image without a calibration phantom, formulas were created to quantitate BMD with a high precision.Type: GrantFiled: February 18, 2011Date of Patent: September 1, 2015Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Matthew J. Budoff, Song Shou Mao, Christopher A. Dailing
-
Publication number: 20150191514Abstract: The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.Type: ApplicationFiled: September 14, 2012Publication date: July 9, 2015Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Ashraf S. Ibrahim, Michael R. Yeaman, John E. Edwards, JR., Guanpingsheng Luo, Yue Fu
-
Publication number: 20140335092Abstract: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.Type: ApplicationFiled: May 15, 2014Publication date: November 13, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. SPELLBERG, Lin LIN, Ashraf IBRAHIM, Guanpingsheng LUO
-
Publication number: 20140335114Abstract: The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.Type: ApplicationFiled: April 17, 2014Publication date: November 13, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Yue FU, Guanpingsheng Luo, Ashraf S. Ibrahim, Brad Spellberg, John E. Edwards, JR.
-
Publication number: 20140329740Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).Type: ApplicationFiled: March 28, 2014Publication date: November 6, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael R. YEAMAN, Arnold S. BAYER
-
Patent number: 8846066Abstract: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.Type: GrantFiled: June 13, 2013Date of Patent: September 30, 2014Assignees: The Regents of the University of California, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael S. Kolodney, Adam M. Rotunda
-
Publication number: 20140275836Abstract: An apparatus including an accelerometer and a microphone contained in a housing that can be placed on a chest of an individual, the accelerometer configured to detect chest motion and microphone to detect respiratory sounds during at least one of inspiration and expiration. A method including placing such an apparatus on a chest of a subject. A method of monitoring an intubation including simultaneously assessing chest movement and air movement sounds in the airway and lungs; and indicating the status of the intubation based on the assessing. A machine-readable medium containing non-transitory program instructions that, when executed, cause a processor to perform a method including assessing chest movement and air movement sounds in a patient; and indicating the status of the intubation based on the assessing.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Ruey-Kang Chang
-
Patent number: 8809263Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).Type: GrantFiled: October 26, 2009Date of Patent: August 19, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael Yeaman, Arnold Bayer
-
Publication number: 20140216449Abstract: A fluid delivery and airway management device including a tubular member dimensioned for introducing a fluid into a trachea of a mammal, the tubular member having a proximal portion, a distal portion, and a middle portion between the proximal portion and the distal portion. The tubular member is dimensioned for positioning of the proximal portion in an oral cavity of a mammal, the middle portion in an oropharynx of the mammal and the distal portion in an esophagus of the mammal. An inflatable oral cavity balloon is positioned at the proximal portion and dimensioned to occlude the oral cavity. An inflatable esophageal balloon is positioned at the distal portion and dimensioned to occlude the esophagus. Apertures may be formed within the middle portion such that a fluid introduced into the tubular member is output through the apertures to a trachea.Type: ApplicationFiled: December 19, 2013Publication date: August 7, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Ruey-Kang Chang
-
Patent number: 8790662Abstract: The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells.Type: GrantFiled: March 12, 2012Date of Patent: July 29, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. Spellberg, Ashraf S. Ibrahim, John E Edwards, Jr.
-
Patent number: 8787625Abstract: Embodiments include methods, devices, software, and systems for identifying a person based on relatively permanent pigmented or vascular skin mark (RPPVSM) patterns in images. Locations of RPPVSMs in different images of people are point matched, and a correspondence probability that the point matched RPPVSMs are from different people is calculated. Other embodiments are also described. Other embodiments are also described and claimed.Type: GrantFiled: April 26, 2012Date of Patent: July 22, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Noah Ames Craft, Wai Kin Adams Kong, Arfika Nurhudatiana
-
Publication number: 20140200219Abstract: The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart.Type: ApplicationFiled: March 17, 2014Publication date: July 17, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Nestor F. Gonzalez-Cadavid, Jacob Rajfer
-
Publication number: 20140166020Abstract: An airway management device including a tubular member dimensioned for introducing air into a trachea of a mammal, the tubular member having a proximal portion, a distal portion, and a middle portion between the proximal portion and the distal portion. The tubular member is dimensioned for positioning of the proximal portion in an oral cavity of a mammal, the middle portion in an oropharynx of the mammal and the distal portion in an esophagus of the mammal. An inflatable oral cavity balloon is positioned at the proximal portion and dimensioned to occlude the oral cavity. An inflatable esophageal balloon is positioned at the distal portion and dimensioned to occlude the esophagus. Apertures may be formed within the middle portion such that air introduced into the tubular member is output through the apertures to a trachea.Type: ApplicationFiled: December 19, 2013Publication date: June 19, 2014Applicant: Los Angeles Biomedical Research Institute at Garbor-UCLA Medical CenterInventor: Ruey-Kang Chang
-
Patent number: 8747846Abstract: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.Type: GrantFiled: May 11, 2012Date of Patent: June 10, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. Spellberg, Lin Lin, Ashraf Ibrahim, Guanpingsheng Luo
-
Publication number: 20140135227Abstract: The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.Type: ApplicationFiled: October 18, 2013Publication date: May 15, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Sharon Adler, Bancha Satirapoj, Ying Wang, Janine LaPage, Cynthia C. Nast
-
Patent number: 8709445Abstract: This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.Type: GrantFiled: July 31, 2008Date of Patent: April 29, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Noah A. Craft, Kevin W. Bruhn, Ron A. Birnbaum
-
Patent number: 8709446Abstract: The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.Type: GrantFiled: July 2, 2010Date of Patent: April 29, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor—UCLA Medical CenterInventors: Yue Fu, Guanpingsheng Luo, Ashraf Ibrahim, Brad Spellberg, John Edwards, Jr.
-
Publication number: 20140112941Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Ashraf S. IBRAHIM, Mingfu LIU, Brad SPELLBERG, Scott FILLER, Yue FU, John E. EDWARDS
-
Publication number: 20140065695Abstract: The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease.Type: ApplicationFiled: May 1, 2013Publication date: March 6, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael R. YEAMAN, Nanette Y. YOUNT, Brad P. Brass
-
Patent number: 8660630Abstract: An apparatus including a chest strip comprising a plurality of precordial and limb leads for an electrocardiogram (ECG) and an ECG data recorder coupled to the chest strip, wherein the ECG data recorder configured to receive signals from the leads. An apparatus including a chest strip comprising a plurality of precordial leads positioned to correspond with desired lead placement for an electrocardiogram (ECG) and an ECG data recorder; a plurality of limb leads coupled to the chest strip, wherein the ECG data recorder is coupled to plurality of precordial leads and the plurality of limb leads and configured to receive electrocardiogram data generated by the plurality of precordial leads and the plurality of limb leads. A method including coupling a chest strip including precordial leads and a data recorder to a newborn, the data recorder configured to receive electrocardiogram data from the precordial leads; and transmitting electrocardiogram data from the data recorder.Type: GrantFiled: June 21, 2011Date of Patent: February 25, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Ruey-Kang Chang